The most common concerns include which foods might cause or trigger atopic dermatitis, when to introduce solid foods, and ...
A long-term analysis offers reassurance to users of the topical treatment recently approved for children down to age 2.
Almirall S.A. (ALM), a global biopharmaceutical company dedicated to medical dermatology, is presenting a broad range of clinical and real‑world data across its portfolio at the 2026 American Academy ...
The Phase 1 study of RLS-1496, the first human trial of a GPX4 (selective glutathione peroxidase 4) modulator, met its primary endpoint and also demonstrated a statistically significant relationship ...
As the 2026 American Academy of Dermatology (AAD) annual meeting approaches, MedPage Today is offering a preview of an upcoming roundtable on new and emerging developments in atopic dermatitis.
Apogee Therapeutics shares rally as Phase 2 APEX data show durable atopic dermatitis control with 3- or 6-month dosing.
Children with moderate to severe atopic dermatitis had improved skin barrier function with 16-week dupilumab treatment in both lesional and nonlesional skin, according to data published in Annals of ...
For children with atopic dermatitis (AD), dupilumab treatment restores skin barrier function, according to a study published online Jan. 26 in the Annals of All ...
Researchers found that dupilumab improved skin barrier integrity and reduced inflammation in children with atopic dermatitis.
Roflumilast cream 0.05% was well-tolerated and effective for the long-term treatment of mild to moderate atopic dermatitis in ...
New research has identified a previously underexplored immune signalling pathway that could help explain persistent inflammation in Atopic Dermatitis (AD), offering fresh insights into potential ...
Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today announced positive, top-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results